NYU Langone offers a postgraduate year two (PGY-2) Oncology Pharmacy Residency program. Residents train on the Manhattan campus, including Kimmel Pavilion and various Perlmutter Cancer Center sites, including Perlmutter Cancer Center—34th Street, NYU Langone Ambulatory Care Center—38th Street, the Blood and Marrow Transplantation and Cellular Therapy Center, and Hassenfeld Children’s Center for Cancer and Blood Disorders.

As a resident in our Oncology Pharmacy Residency program, you will receive comprehensive training that allows you to develop clinical expertise in oncology pharmacotherapy. The primary emphasis of the program is to train clinicians to care for patients with cancer in both hospital and outpatient settings.

This program is in American Society of Health-System Pharmacists (ASHP) pre-candidate status.

Attend a Virtual Information Session

Members of the oncology pharmacy team will provide a brief overview of the program and be available to answer any questions you may have regarding rotations, longitudinal experiences, teaching opportunities, and residency life.

We are hosting virtual information sessions about the program on the following dates:

• November 24, 2025, from 5:00 to 6:00PM ET
• December 18, 2025, from 5:00 to 6:00PM ET

Fill out this form to register for the information sessions.

If you are attending the ASHP Midyear Clinical Meeting and Exhibition, please stop by the NYU Langone Health booth to learn more about our program.

Oncology Pharmacy Residency Curriculum

Required Rotations

The PGY-2 Oncology Pharmacy Residency curriculum consists of the following requirements:

• Orientation (4–5 weeks)
• Inpatient Malignant Hematology (6 weeks)
• Inpatient Bone Marrow Transplant/Cellular Therapies (6 weeks)
• Ambulatory Hematologic Malignancies (4 weeks)
• Ambulatory Oncology (i.e., thoracic malignancies, breast cancer, gastrointestinal malignancies, sarcoma, gynecologic malignancies) (8–9 weeks)
• Ambulatory Bone Marrow Transplant/Cellular Therapies (4 weeks)
• Inpatient Pediatric Hematology/Oncology (4 weeks)
• Inpatient Oncology Elective II/Preceptorship (4–5 weeks)
• Research (4–5 weeks)
• Elective (4–5 weeks)

Elective Rotations

Residents may choose an elective (approximately four weeks) from the following rotations:

• Inpatient Malignant Hematology II
• Inpatient Medical Oncology
• Ambulatory Hematology Malignancies II
• Inpatient BMT/Cellular Therapies II
• Ambulatory BMT/Cellular Therapies II
• Inpatient Pediatric Hematology/Oncology
• Ambulatory Pediatric Hematology/Oncology
• Investigational Drug Services
• Transplant (both cellular and solid organ Infectious Diseases)

Oncology Pharmacy Residency Research Requirements

Residents are required to complete a scholarly research project in oncology. We encourage you to choose a topic of interest that contributes to the advancement of oncology pharmacotherapy.

Oncology Pharmacy Residency Longitudinal Experiences

Residents have the following longitudinal experiences:

• a scholarly research project, with results presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting
• leadership and medication safety
• oncology pharmacy informatics
• oncology pharmacy operations and administration
• clinical weekend on-call, rotating weekends

You will interact with residents in the PGY-1 Pharmacy Practice Residency—Manhattan during clinical rotations. You will also participate in the development of oncology policies and protocols, assist with oncology treatment plans and order set builds, and complete drug monograph reviews.

Oncology Pharmacy Residency Educational Activities

The Oncology Pharmacy Residency program includes several educational activities:

• Clinical presentations: patient-case presentations (two per year), roundtable discussions (two per year), and a continuing education lecture. You will also have the opportunity to develop your teaching skills by providing in-service presentations to providers, nurses, and pharmacy staff.
• Oncology journal watch: a collaborative discussion series in which the oncology pharmacy resident and oncology preceptors meet to review the latest published studies in oncology. Each participant will be prepared to discuss one to two studies, highlighting any practice-changing data and potential emerging therapeutic trends (six per year).
• C.H.E.M.O didactic series: a foundational discussion with a designated preceptor, exploring the full spectrum of oncology pharmacotherapy, including cytotoxic chemotherapy, hormonal therapies, emerging immunotherapies, molecularly targeted agents (i.e., TKIs), and oncology supportive care. Each session will review key principles within these topics, including mechanisms, adverse effects, monitoring strategies, and clinical applications.
• Perlmutter Cancer Center pharmacy newsletter: the resident will act as author and editor for the newsletter, which will include oncology practice pearls, drug formulary additions, pharmacy workflow improvements, and departmental and medication safety updates.

Oncology Pharmacy Residency Stipend and Benefits

Residents will receive a stipend of $65,000, as well as comprehensive health insurance, 14 vacation days, and 7 professional conference days.

Oncology Pharmacy Residency Eligibility Requirements

Applications to our Oncology Pharmacy Residency program must possess a PharmD degree from an Accreditation Council for Pharmacy Education (ACPE)–accredited college or school of pharmacy. Applicants must also have completed or be slated to complete a PGY-1 Pharmacy Practice Residency prior to the start date and be licensed or eligible for licensure in New York State.

Oncology Pharmacy Residency Application Process

We offer one PGY-2 position per year. Applicants must submit their application through the Pharmacy Online Residency Centralized Application Service (PhORCAS) and participate in the ASHP Resident Matching Program. The resident matching program code is 22996.

To apply, submit the following materials through PhORCAS by January 5, 2026:

• all official college transcripts
• your CV
• three references submitted using the reference form in PhORCAS
• a letter of intent that describes your goals and interests, motivation for completing a PGY-2 Oncology Pharmacy Residency, and why you want to be a part of NYU Langone’s Perlmutter Cancer Center

An interview is required and will include a patient case presentation.

The start date for the program is July 1, 2026.

Contact Us

For questions related to the Oncology Pharmacy Residency program, including information on registering for our virtual information sessions, please reach out to Francis Andrew De Los Reyes, director of the PGY2 Oncology Pharmacy Residency program, at FrancisAndrew.DeLosReyes@NYULangone.org.